Modern meals are easy to eat — and easy to absorb quickly.
That often leads to a familiar pattern:You eat, feel fine at first, and then a few hours later feel tired, hungry, or start craving something sweet.
This is not just about willpower.It’s about how quickly energy enters your system.
SiPore® is designed to act at that exact moment — during digestion.
How SiPore® works
1. Taken
Post highlights: -What “metabolically healthy” really means -Why metabolic health affects energy, appetite, and long-term wellbeing -How modern meals can place stress on metabolism -Signs of healthy metabolic function -Simple habits that support metabolic health -How supporting steadier post-meal responses may help maintain metabolic balance
Modern food is designed for speed, taste, and convenience. It is not designed around how the body processes energy. Many meals today are rich in carbohydrates and fats that are broken down and absorbed very quickly. When energy enters the system rapidly, it can lead to sharp rises after eating followed by dips later on.
Those dips are familiar to many people. You eat lunch, feel fine at f
Sigrid Therapeutics (Sigrid), a science-driven consumer health company developing innovative solutions for metabolic health, today announced the appointment of Claus Kjaersgaard as its new Chief Executive Officer. Claus will assume the role on 1 February 2026.
Sigrid today announced that it has entered into an exclusive global licensing and research collaboration with a leading multinational consumer health company to expand the SiPore® technology platform into consumer oral health through a partner-led approach.
Stockholm — January 21, 2026 — Sigrid Therapeutics (Sigrid) is a Swedish-based, science-driven consumer health company with a primary focus on metabolic health. Following the successful launch of its first two clinically proven products — Carb Fence , developed to support weight loss by reducing appetite and sugar cravings while promoting fat loss and preserving muscle mass , and Glucose Stabi
Sigrid, a Swedish innovation company in consumer health, today announces that the company has raised SEK 45 million in new capital.
After an exceptionally successful online launch earlier this year, Sigrid Therapeutics and Kronans Apotek are now ready to take the next step: SIGRID Stabiliser will be launched on store shelves across the country in the fall of 2025.
Sigrid Therapeutics AB (Sigrid) announces that CEO Sana Alajmovic will leave her operational role on January 31, 2026 to take up a new position outside of Sigrid's operations and that does not compete with the company.
SIGRID, the Swedish innovative consumer health company behind the patented SiPore® technology, today reports new clinical and commercial milestones for its innovative dietary supplement Glucose Stabiliser.
Sigrid Therapeutics (Sigrid) today announced that it has secured U.S. marketing approval for its patented SiPore® technology, following the successful SHINE study, the largest study of its kind in prediabetes.
Sigrid Therapeutics announces today that their innovative product, Sigrid Stabiliser, which was previously only available through the company's own e-commerce, will now be launched and offered exclusively at Kronans Apotek starting in February 2025.
Sigrid Therapeutics today announced the signing of a strategic partnership with GetHealthy.store, a leading US provider of e-commerce solutions for healthcare providers selling healthcare and nutritional products.
Sigrid Therapeutics announced today that recruitment to the SHINE clinical trial, which is evaluating the company's breakthrough product SiPore21® for long-term diabetes control, has been completed.
Sigrid Therapeutics announced today that the company has recruited over 50% of patients in SHINE, a clinical trial evaluating SiPore21® for the treatment of elevated glucose levels.
Sigrid Therapeutics today announced that the company has launched Glucose Stabiliser in the US.
Sigrid Therapeutics has secured SEK 44 million in a successful and oversubscribed financing round, underscoring the strong confidence of investors in Sigrid's innovative SiPore technology®.
Sigrid Therapeutics is pleased to announce the start of the SHINE clinical trial for SiPore21® – an innovative medical device designed for long-term maintenance of blood sugar and weight control.
Sigrid Therapeutics (Sigrid), a Swedish consumer healthcare company, announced today that Professor Iain Chapple, a world-leading expert in oral health from the University of Birmingham's College of Medical and Dental Sciences, has been appointed as the company's scientific advisor.
Sigrid Therapeutics, an innovative, consumer-focused health company, today presented the results of a consumer trial ahead of the launch of their clinically proven SiPore® technology for blood sugar control in prediabetics and type 2 diabetics.